Replies to post #243150 on Innovation Pharmaceuticals Inc (IPIX)

[farrell90]

I received a PM asking why I have invested in IPIX. The following is my reply.

It may prove crazy but I bought more today.

Why? I believe in the science. Plus, IPIX has received a non binding term sheet; and I believe it is actively negotiating a partnership deal.

IMO Brilacidin has 3 solid phase 2 studies:

1. ABBSI was a well done study where a single dose IV Brilacidin proved equivalent to Daptomycin.

2.Ulcerative proctitis proof of concept study demonstrated remarkable results in a small number of patients. The IBD market is enormous, but larger studies will be needed. The "big Pharma" company is also interested in Brilacidin for IBD.

3.Oral Mucositis is a horrible debilitating disease which responded to a swish of Oral Brilacidin. Brilacidin for OM was most effective in the most commonly utilized high dose Cis Platinum treatment. IPIX's last PR showed Brilacidin is very competitive with other IV OM meds in clinical trials.

When I first invested in IPIX my hope was to have at least one of the pharmaceuticals be successful. IMO Brilacidin will prove to be a clinical and financial success. The term sheet is just for OM and IBD. All the other indications ,including all the dermatologic indications, are currently being retained. IMO the derm applications, acne, hiadenitis suppriva,eczema,psoriasis,skin infections,and diabetic ulcers will prove to be the most profitable. I expect a partnership deal for Brilacidin to be announced soon.

Kevetrin stage 1 study for solid tumors showed clinical responses in a number of tumors, especially in Ovarian Carcinomas.The 2 patient stage 2 study confirmed Kevetrin activated P 53 in Ovarian cancer cells. Unfortunately IPIX does not currently have the resources for additional trials, I am optimistic Kevetrin studies will be continued. The FDA was impressed enough to award Kevetrin
Orphan Drug status for Ovarian Cancer, Pancreatic Cancer, and Retinoblastoma as well as Rare Pediatric Disease designation for childhood Retinoblastoma.

The Prurisol stage 2a study showed a positive response trend for higher doses of Prurisol. Hopefully the stage 2b study which was done at even higher doses will confirm the positive trend noted in the earlier study. The unexplained CRO payment controversy does cast a shadow on the study.The results of the stage 2b almost certainly will be released soon.

Unfortunately IPIX's financial status is dire. So far it has been able to fund the clinical trials without debt which will give it some time to secure funding. In spite of the financial stress IPIX's management seems upbeat. IMO IPIX's risk of bankrupcy has been overplayed by its critics.

IMO IPIX has the goods with Brilacidin and will secure a partnership and funding. Their financial status means they are not going to negotiate the best possible deal,but any deal will send the stock soaring.

All of the above is just my opinion. Investors should not invest money they can not afford to lose. IPIX's financial difficulties have resulted in very low share prices. My bet is the low prices are temporary but I may be completely wrong.

Good luck, Farrell

[pix]

Hi Nerby
That is also my last hope scenario...
Was really wondering about the 3 Milestone package they signed with Aspire at that time.

Good luck to all

Pix

[TheDane]

I think for Aspire to have signed onto the deal IPIX must have already had serious interest from potential partners and didn’t have to shop B around. I agree Aspire has been dumping their shares once it became obvious the milestones wouldn’t be met. Did they read about it in the 10-k like we did? It’s also likely that the end of Sept. was a deadline for the selling that occurred this week.

I don’t see why IPIX would go into bankruptcy. They have no debt that would force them into that and they have plenty of shares to sell. I hope that doesn’t happen, the share selling, but bancruptcy seems rather unlikely with numerous successful trials completed and a term sheet from a global bio Pharma.

[DesireToLearn]

We'll likely see some form of capital infusion before a deal is signed. Just not sure how much or what type. My guess is enough to pay CRO and payroll.